To listen to individual tracks, click on the track you wish to listen to. To download tracks, right-click on the one you wish to download.
Track 1	Case from the practice of Alan B Astrow, MD: A 29-year-old nursing student underwent a right mastectomy for two 3-cm, Grade III, ER-positive, PR-positive, HER2-positive infiltrating ductal cancers (IDC) in the right breast. Five axillary nodes were positive, and the patient is now being considered for adjuvant systemic therapy.
Track 2	Case from the practice of Mary Ann K Allison, MD: A 39-year-old woman at 21 weeks’ gestation with her second pregnancy presented with a 4 x 3.1-cm, triple-negative IDC and a palpable lymph node that was positive for malignant cells on FNA. The tumor is BRCA1-positive, and the patient’s mother died of breast cancer at the age of 29. The patient desires breast-conserving surgery, but the surgeon states that tumor shrinkage would be required.
Track 3	Case from the practice of Robert A Moss, MD: A 77-year-old otherwise healthy physician’s wife presented with a 5.5-cm, left-sided, ER-positive, PR-positive, HER2-negative infiltrating lobular carcinoma with one of three sentinel nodes positive. The patient wishes to avoid chemotherapy, if possible.
Track 4	Case from the practice of Dr Astrow: A 61-year-old woman who was treated with adjuvant AC and five years of tamoxifen for left-sided, node-positive breast cancer presented eight years after initial diagnosis with biopsy-proven metastatic breast cancer to the left lung. She was treated with letrozole for three years, then developed symptomatic progression of mediastinal and hilar lymph node metastases, for which she received radiation therapy and fulvestrant. After disease progression, the patient was treated with capecitabine but developed a malignant pericardial effusion, treated with a pericardial window.
Track 5	Case from the practice of Dr Allison: A 58-year-old woman with a 4-cm, Grade III, ER-negative, HER2-positive IDC and synchronous bone and liver metastases was enrolled on the TORI B-03 trial of trastuzumab and bevacizumab. She experienced tumor response and disease stabilization for two years, at which time she desired less frequent therapy and was treated off study with trastuzumab alone every three weeks. She received further lines of chemotherapy/anti-HER2 treatment upon disease progression but was intolerant of lapatinib because of intractable diarrhea. She then developed back pain from progressive bone metastases.
Track 6	Case from the practice of Dr Moss: A 69-year-old emotionally fragile woman who underwent mastectomy and undetermined “low-dose chemotherapy” 14 years earlier for right-sided, node-negative breast cancer presented with a chest wall abnormality. Biopsy revealed a poorly differentiated, ER-positive, PR-negative, HER2-negative adenocarcinoma consistent with primary breast cancer. MRI revealed extensive right chest wall involvement, including skin, pectoral muscles and axillary nodes. The chest wall was indurated, erythematous and pruritic.
Track 7	Case presented by an audience member: A 41-year-old nurse who underwent mantle radiation therapy 21 years ago for Stage IIA Hodgkin disease presented with a 1.3-cm, poorly differentiated, triple-negative, p53-positive, node-negative breast cancer.